Rigel Pharmaceuticals appoints Kamil Ali-Jackson to board, expanding board to 10 members

RIGEL PHARMACEUTICALS INC

Board size increased from 9 to 10; Ali-Jackson appointed effective Dec. 16, 2021, term expires at 2022 annual meeting.
Standard non-employee director compensation: $50k annual retainer, initial option grant for 120,000 shares vesting over 3 years.
Ali-Jackson determined independent under SEC and Nasdaq rules; no transactions requiring disclosure under Item 404(a).
Not appointed to any standing board committee at this time.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Kamil Ali-Jackson

Director

RIGL · RIGEL PHARMACEUTICALS INC

Effective: 2021-12-16
Filed: December 17, 2021, 6:59 PM ET

On the Effective Date, the Board appointed, upon the recommendation of the Board’s Corporate Governance, Health Care Compliance Oversight and Nominating Committee, Kamil Ali-Jackson to fill in the vacancy on the Board and to serve as a member of the Board until her successor is elected and has qualified, or sooner in the event of her death, resignation or removal.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Kamil Ali-Jackson was appointed as Director at RIGEL PHARMACEUTICALS INC.

Action: appointed
Role: Director

Exact text from the filing

On the Effective Date, the Board appointed, upon the recommendation of the Board’s Corporate Governance, Health Care Compliance Oversight and Nominating Committee, Kamil Ali-Jackson to fill in the vacancy on the Board and to serve as a member of the Board until her successor is elected and has qualified, or sooner in the event of her death, resignation or removal.

View on SEC.gov

RIGEL PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001104659-21-151192

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.